The decay of HIV under anti-retroviral therapy is biphasic even in humanized mice with just T cells

HIV-1 plasma viral load decays in a biphasic manner during antiretroviral therapy (ART). It was hypothesized that this is due to infection of different cell types, namely CD4+ T cells and macrophages. We studied this possibility directly by modeling the decay of HIV-1 in humanized mice. We utilized previously published data from humanized T-cell only mice (TOM) and myeloid-only mice (MOM) infected with HIV-1 and treated with a potent ART regimen. Viral load decay dynamics were modeled using either a single or a biexponential decay fitted using nonlinear mixed effects techniques. Fits were compared using the corrected Bayesian information criterion (BICc). In TOM, the biphasic model was significantly better than a single-phase decay model (ΔBICc ≈ 16) despite additional parameters. In MOM, the biphasic decay was statistically better, but there was substantial uncertainty because the virus goes below detection very fast. The first-phase half-life was consistent between groups (1.2 days in MOM and 1.3 days in TOM) and similar to the half-life estimated in human infection. The second-phase decay in these mice was minimal likely due to low initial viral loads. Additional analyses with mice containing both CD4+ T cells and macrophages or X4-tropic virus-infected MOM mice confirmed the biphasic pattern, demonstrating the robustness of this result. The biphasic decline in HIV-1 occurs, even with only CD4+ T cells, refuting the hypothesis that distinct cell populations (CD4+ T cells and macrophages) drive each decay phase. These findings support an alternative model in which the observed dynamics arise from intrinsic properties of the viral infection lifecycle rather than from cellular compartmentalization.IMPORTANCEIt is well known that when antiretroviral therapy is started in people infected with HIV, the decay of virus in the periphery is biphasic early on (followed by other slower phases). One possibility for this pattern of decay is infection of two different types of cells (suggested previously to be CD4+ T cells and macrophages), with different turnovers giving rise to the biphasic decline. We addressed this issue directly in a humanized mouse model of HIV, taking advantage of mice reconstituted with just T cells and treated with antiretroviral drugs. We found that the observed decay is biphasic, which eliminates the hypothesis that the biphasic decline is due to the co-existence of the two types of cells. It is possible that integration dynamics, as we previously proposed, are responsible for the observed biphasic decline.

Authors

Institutions

Publication Details

Journal
Journal of Virology
Published
2025-12-30
DOI
https://doi.org/10.1128/jvi.01321-25
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The decay of HIV under anti-retroviral therapy is biphasic even in humanized mice with just T cells

Jenna B. Honeycutt, Elisabete Fernandes, Ruy M. Ribeiro, Angela Wahl et al.
Journal of Virology
HIV Research and Treatment
article

The decay of HIV under anti-retroviral therapy is biphasic even in humanized mice with just T cells

Jenna B. Honeycutt, Elisabete Fernandes, Ruy M. Ribeiro, Angela Wahl, J. Victor Garcia, Jasmine A. F. Kreig
article en

Abstract

HIV-1 plasma viral load decays in a biphasic manner during antiretroviral therapy (ART). It was hypothesized that this is due to infection of different cell types, namely CD4+ T cells and macrophages. We studied this possibility directly by modeling the decay of HIV-1 in humanized mice. We utilized previously published data from humanized T-cell only mice (TOM) and myeloid-only mice (MOM) infected with HIV-1 and treated with a potent ART regimen. Viral load decay dynamics were modeled using either a single or a biexponential decay fitted using nonlinear mixed effects techniques. Fits were compared using the corrected Bayesian information criterion (BICc). In TOM, the biphasic model was significantly better than a single-phase decay model (ΔBICc ≈ 16) despite additional parameters. In MOM, the biphasic decay was statistically better, but there was substantial uncertainty because the virus goes below detection very fast. The first-phase half-life was consistent between groups (1.2 days in MOM and 1.3 days in TOM) and similar to the half-life estimated in human infection. The second-phase decay in these mice was minimal likely due to low initial viral loads. Additional analyses with mice containing both CD4+ T cells and macrophages or X4-tropic virus-infected MOM mice confirmed the biphasic pattern, demonstrating the robustness of this result. The biphasic decline in HIV-1 occurs, even with only CD4+ T cells, refuting the hypothesis that distinct cell populations (CD4+ T cells and macrophages) drive each decay phase. These findings support an alternative model in which the observed dynamics arise from intrinsic properties of the viral infection lifecycle rather than from cellular compartmentalization.IMPORTANCEIt is well known that when antiretroviral therapy is started in people infected with HIV, the decay of virus in the periphery is biphasic early on (followed by other slower phases). One possibility for this pattern of decay is infection of two different types of cells (suggested previously to be CD4+ T cells and macrophages), with different turnovers giving rise to the biphasic decline. We addressed this issue directly in a humanized mouse model of HIV, taking advantage of mice reconstituted with just T cells and treated with antiretroviral drugs. We found that the observed decay is biphasic, which eliminates the hypothesis that the biphasic decline is due to the co-existence of the two types of cells. It is possible that integration dynamics, as we previously proposed, are responsible for the observed biphasic decline.

Journal of VirologyVol. 100(2)
University of North Carolina at Chapel Hill (US), Los Alamos National Laboratory (US), University of Lisbon (PT), AIDS Clinical Trials Group (US), University of Alabama at Birmingham (US)
Good health and well-being
Openalex Percentile: Top 33%
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.